Back to top
more

QuidelOrtho (QDEL)

(Delayed Data from NSDQ)

$24.40 USD

24.40
1,724,666

+0.96 (4.10%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $24.42 +0.02 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Quidel (QDEL) Q3 Earnings Beat Estimates

by Zacks Equity Research

Quidel (QDEL) delivered earnings and revenue surprises of 26.20% and -0.01%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Can Diagnostics Aid Hologic (HOLX) Q4 Sales Amid Coronavirus?

by Zacks Equity Research

Strength in Molecular Diagnostics business is likely to have continued to aid Hologic's (HOLX) performance in the fourth quarter of fiscal 2020 amid the coronavirus-led economic doldrums.

Zacks Equity Research

Owens & Minor (OMI) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Owens & Minor's (OMI) PPE sales are likely to have maintained its momentum during Q3, thus driving the top line.

Zacks Equity Research

STERIS (STE) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Within Life Sciences, STERIS (STE) might have registered benefit from pharma customers on growing vaccines and biologics businesses in Q2.

Zacks Equity Research

DexCom (DXCM) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

DexCom's (DXCM) third-quarter results benefit from solid segmental performance.

Zacks Equity Research

Quidel (QDEL) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Quidel's (QDEL) fiscal third-quarter results are likely to reflect solid show by Subscriptions and Managed Services segments.

Zacks Equity Research

Masimo (MASI) Earnings and Revenues Beat Estimates in Q3

by Zacks Equity Research

Masimo (MASI) continues to gain from key Product segment, which witnessed solid growth in Q3.

Zacks Equity Research

Varian (VAR) Earnings and Revenues Surpass Estimates in Q4

by Zacks Equity Research

Varian's (VAR) receipt of 10 Ethos orders in Q4 instills optimism

Zacks Equity Research

Henry Schein (HSIC) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Henry Schein's (HSIC) medical business' PPE sales are likely to have maintained its momentum along with global recovery trends of the dental business during Q3.

Zacks Equity Research

Quidel (QDEL) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Quidel (QDEL) is likely to have witnessed an uptick in rapid immunoassay revenues in Q3.

Zacks Equity Research

Ecolab (ECL) Earnings and Revenues Surpass Estimates in Q3

by Zacks Equity Research

Although Ecolab's (ECL) third-quarter results reflect weakness in the Global Industrial and Institutional segments, its Global Healthcare and Life Sciences unit shows strength.

Zacks Equity Research

Is Quidel (QDEL) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (QDEL) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

What's in Store for IDEXX Laboratories (IDXX) in Q3 Earnings?

by Zacks Equity Research

IDEXX's (IDXX) third-quarter top line is likely to have benefited from strength in CAG and LPD businesses.

Zacks Equity Research

Illumina (ILMN) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Illumina (ILMN) is upbeat about its third-quarter sequencing consumable revenue growth.

Zacks Equity Research

Quidel (QDEL) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Quidel (QDEL) closed at $245.74 in the latest trading session, marking a +1.55% move from the prior day.

Zacks Equity Research

Quidel (QDEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Quidel (QDEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Quest Diagnostics' (DGX) Q3 Earnings Beat, Base Volume Rises

by Zacks Equity Research

In Q3, Quest Diagnostics (DGX) sees strong signs of the health care system returning to pre-pandemic levels

Zacks Equity Research

Align Technology (ALGN) Beats on Q3 Earnings, Margins Up

by Zacks Equity Research

Align Technology's (ALGN) segments report solid rebound in sales across geographies despite the pandemic-led business challenges.

Zacks Equity Research

Edwards Lifesciences (EW) Beats on Q3 Earnings, Margins Up

by Zacks Equity Research

Despite coronavirus-led business challenges, Edwards Lifesciences (EW) witnessed steady improvement in TAVR procedure volumes in Q3.

Zacks Equity Research

Quidel, Akoustis Technologies, Netflix, Snap and Texas Instruments highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Quidel, Akoustis Technologies, Netflix, Snap and Texas Instruments highlighted as Zacks Bull and Bear of the Day

Kevin Cook headshot

Bull of the Day: Quidel (QDEL)

by Kevin Cook

Rapid COVID-19 tests that also screen influenza A+B have vaulted sales and profit growth 200-400%

Zacks Equity Research

Agios (AGIO) Withdraws Filing for Leukemia Drug Tibsovo in EU

by Zacks Equity Research

Agios (AGIO) withdraws the regulatory filing for Tibsovo in Europe, which was developed to treat relapsed/refractory acute myeloid leukemia in adult patients with a susceptible IDH1 mutation.

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for October 16th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 16th

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for October 8th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 8th

Kevin Cook headshot

Big October Winners: CRISPR, Alteryx, NVIDIA, Quidel

by Kevin Cook

Two women will share the Nobel prize for a gene editing technology that will change the world.